Clinical trial results:
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES

Summary

EudraCT number	2010-020852-79
Trial protocol	CZ LT FI NL FR HU BE EE SE PL AT GR IT BG
Global end of trial date	10 August 2016

Results information

Result version number	v1 (current)
This version publication date	16 February 2017
First version publication date	16 February 2017

Trial information

Trial identification

Sponsor protocol code	A0081041

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, 110017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 August 2016
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	10 August 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of 2 dose levels of pregabalin (Level 1: 2.5 mg/kg/day [maximum 150 mg/day] and Level 2: 10 mg/kg/day [maximum 600 mg/day]) compared to placebo as an adjunctive treatment in reducing the frequency of partial onset seizures in pediatric subjects 4 to 16 years of age.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 September 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 8
Country: Number of subjects enrolled	Bulgaria: 2
Country: Number of subjects enrolled	Czech Republic: 5
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Greece: 4
Country: Number of subjects enrolled	Hungary: 48
Country: Number of subjects enrolled	Israel: 1
Country: Number of subjects enrolled	Italy: 3
Country: Number of subjects enrolled	Korea, Republic of: 7
Country: Number of subjects enrolled	Malaysia: 4
Country: Number of subjects enrolled	Philippines: 64
Country: Number of subjects enrolled	Poland: 13
Country: Number of subjects enrolled	Romania: 27
Country: Number of subjects enrolled	Serbia: 14
Country: Number of subjects enrolled	Singapore: 8
Country: Number of subjects enrolled	Turkey: 6
Country: Number of subjects enrolled	Ukraine: 55
Country: Number of subjects enrolled	United States: 20

Worldwide total number of subjects	295
EEA total number of subjects	116

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	173
Adolescents (12-17 years)	122
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The subjects for the study were enrolled from 18 countries. The study start date was 29-Sep-2011 and the study completion date was 10-Aug-2016.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

Arms

Are arms mutually exclusive?	Yes
Arm title	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day

Arm description:

Subjects aged 4 to 16 years and less than (<) 30 kilograms (kg) in weight, received pregabalin 3.5 milligram per kilogram per day (mg/kg/day) (up to a maximum of 150 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and greater than or equal to (>=) 30 kg in weight, received pregabalin 2.5 mg/kg/day (up to a maximum of 150 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Arm type	Experimental
Investigational medicinal product name	Pregabalin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects aged 4 to 16 years and < 30 kilograms (kg) in weight, received pregabalin 3.5 mg/kg/day (up to a maximum of 150 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and >= 30 kg in weight, received pregabalin 2.5 mg/kg/day (up to a maximum of 150 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Arm title	Pregabalin: 10 mg/kg/day or 14 mg/kg/day

Arm description:

Subjects aged 4 to 16 years and < 30 kg in weight, received pregabalin 14 mg/kg/day (up to a maximum of 600 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and >= 30 kg in weight, received pregabalin 10 mg/kg/day (up to a maximum of 600 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Arm type	Experimental
Investigational medicinal product name	Pregabalin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, Oral solution
Routes of administration	Oral use

Dosage and administration details:

Subjects aged 4 to 16 years and < 30 kilograms (kg) in weight, received pregabalin 14 mg/kg/day (up to a maximum of 600 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and >= 30 kg in weight,

received pregabalin 10 mg/kg/day (up to a maximum of 600 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Arm title	Placebo

Arm description:

Subjects aged 4 to 16 years received placebo matched to pregabalin, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects <30 kg in weight received placebo in the form of oral solution while subjects >=30 kg in weight received placebo in the form of oral solution or capsule.

Arm type	No intervention

No investigational medicinal product assigned in this arm

Number of subjects in period 1	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo
Started	104	97	94
Completed	94	81	84
Not completed	10	16	10
Adverse event, serious fatal	-	1	-
Consent withdrawn by subject	1	2	2
Adverse event, non-fatal	1	4	-
Insufficient Clinical Response	3	4	5
Protocol deviation	3	4	3
Other Unspecified	2	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day

Reporting group description:

Subjects aged 4 to 16 years and less than (<) 30 kilograms (kg) in weight, received pregabalin 3.5 milligram per kilogram per day (mg/kg/day) (up to a maximum of 150 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and greater than or equal to (>=) 30 kg in weight, received pregabalin 2.5 mg/kg/day (up to a maximum of 150 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Reporting group title	Pregabalin: 10 mg/kg/day or 14 mg/kg/day

Reporting group description:

Subjects aged 4 to 16 years and < 30 kg in weight, received pregabalin 14 mg/kg/day (up to a maximum of 600 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and >= 30 kg in weight, received pregabalin 10 mg/kg/day (up to a maximum of 600 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Reporting group title	Placebo

Reporting group description:

Subjects aged 4 to 16 years received placebo matched to pregabalin, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects <30 kg in weight received placebo in the form of oral solution while subjects >=30 kg in weight received placebo in the form of oral solution or capsule.

Reporting group values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo
Number of subjects	104	97	94
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	62	59	52
Adolescents (12-17 years)	42	38	42
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	10.2	10.1	10.3
standard deviation	± 3.9	± 3.5	± 3.7
Gender, Male/Female Units: Subjects			
Female	52	41	40
Male	52	56	54

Reporting group values	Total		
Number of subjects	295		

Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	173		
Adolescents (12-17 years)	122		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age Continuous Units: years			
arithmetic mean			
standard deviation	-		
Gender, Male/Female Units: Subjects			
Female	133		
Male	162		

End points

End points reporting groups

Reporting group title	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day

Reporting group description:

Subjects aged 4 to 16 years and less than (<) 30 kilograms (kg) in weight, received pregabalin 3.5 milligram per kilogram per day (mg/kg/day) (up to a maximum of 150 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and greater than or equal to (>=) 30 kg in weight, received pregabalin 2.5 mg/kg/day (up to a maximum of 150 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Reporting group title	Pregabalin: 10 mg/kg/day or 14 mg/kg/day

Reporting group description:

Subjects aged 4 to 16 years and < 30 kg in weight, received pregabalin 14 mg/kg/day (up to a maximum of 600 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and >= 30 kg in weight, received pregabalin 10 mg/kg/day (up to a maximum of 600 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Reporting group title	Placebo

Reporting group description:

Subjects aged 4 to 16 years received placebo matched to pregabalin, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects <30 kg in weight received placebo in the form of oral solution while subjects >=30 kg in weight received placebo in the form of oral solution or capsule.

Primary: Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase

End point title	Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase[1]

End point description:

All partial onset seizures experienced during baseline phase were recorded by the subjects or their parents/legal guardian, in a daily seizure diary. 28-day seizure rate for all partial onset seizures = ([number of seizures in the baseline phase] divided by [number of days in baseline phase minus {−} number of missing diary days in baseline phase])*28. For log-transformation, the quantity 1 was added to the 28-day seizure rate for all subjects to account for any possible "0" seizure incidence. This resulted in final calculation as: log transformed (28-day seizure rate +1).

End point type	Primary

End point timeframe:

Baseline phase (up to 8 weeks prior to treatment phase [Day 1])

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: For baseline, Only descriptive data was planned to be analyzed for this endpoint.

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	97	93	
Units: Seizures per 28 days				
arithmetic mean (standard deviation)	3.27 (± 1.215)	3.19 (± 1.269)	3.18 (± 1.302)	

Statistical analyses

No statistical analyses for this end point

Primary: Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During 12-Week Treatment Phase

End point title	Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During 12-Week Treatment Phase

End point description:

All partial onset seizures experienced during treatment phase were recorded by the subjects or their parents/legal guardian in a daily seizure diary. 28-day seizure rate for all partial onset seizures = ([number of seizures in the treatment phase] divided by [number of days in treatment phase minus {−} number of missing diary days in treatment phase])*28. For log-transformation, the quantity 1 was added to the 28-day seizure rate for all subjects to account for any possible "0" seizure incidence. This resulted in final calculation as: log transformed (28-day seizure rate +1).

End point type	Primary

End point timeframe:

Day 1 up to Week 12

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	103	96	93	
Units: Seizures per 28 days				
least squares mean (standard error)	2.86 (± 0.07)	2.74 (± 0.072)	2.96 (± 0.073)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

Linear Model With Log transformed baseline seizure rate as continuous covariate and geographic regions, treatment groups and weight as fixed effects.

Comparison groups	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day v Placebo
Number of subjects included in analysis	196
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2577
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.29
upper limit	0.08
Variability estimate	Standard error of the mean
Dispersion value	0.092

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Linear Model With Log transformed baseline seizure rate as continuous covariate and geographic regions, treatment groups and weight as fixed effects.	
Comparison groups	Pregabalin: 10 mg/kg/day or 14 mg/kg/day v Placebo
Number of subjects included in analysis	189
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0185
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.41
upper limit	-0.04
Variability estimate	Standard error of the mean
Dispersion value	0.094

Secondary: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 28-day Seizure Rate During the 12 Week Treatment Phase

End point title	Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 28-day Seizure Rate During the 12 Week Treatment Phase
End point description:	
Percentage of subjects with 50 percent (%) or greater reduction from baseline in 28-day seizure rate during the 12 week treatment phase were reported. 28-day seizure rate for all partial onset seizures = ([number of seizures in the treatment phase] divided by [number of days in treatment phase minus {–} number of missing diary days in treatment phase])*28.	
End point type	Secondary
End point timeframe:	
Day 1 up to Week 12	

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	97	93	
Units: percentage of subjects				
number (not applicable)	29.1	40.6	22.6	

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

P-values were from a Logistic Regression Model including fixed effects for treatment, weight group, and geographical region.

Comparison groups	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day v Placebo
Number of subjects included in analysis	197
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8024
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.036
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.528
upper limit	2.03

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

P-values were from a Logistic Regression Model including fixed effects for treatment, weight group, and geographical region.

Comparison groups	Pregabalin: 10 mg/kg/day or 14 mg/kg/day v Placebo
Number of subjects included in analysis	190
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0092
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.636
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.851
upper limit	3.147

Other pre-specified: Number of Subjects With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 7 days after last dose of study drug (up to 13 weeks) that were absent before treatment or that worsened

relative to pre- treatment state. AEs included both serious and non-serious adverse events.

End point type	Other pre-specified

End point timeframe:

Day 1 up to 7 days after last dose of study drug (up to 13 weeks)

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	97	94	
Units: subjects				
AEs	67	68	56	
SAEs	5	10	7	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point description:

Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 7 days after last dose of study drug (up to 13 weeks) that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to drug was assessed by the investigator. AEs included both serious and non-serious adverse events.

End point type	Other pre-specified

End point timeframe:

Day 1 up to 7 days after last dose of study drug (up to 13 weeks)

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	97	94	
Units: subjects				
AEs	37	46	30	
SAEs	1	1	1	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Adverse Events by Severity

End point title	Number of Adverse Events by Severity

End point description:

An AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. AEs were classified according to the severity in 3 categories a) mild: AEs does not interfere with subject's usual function b) moderate: AEs interferes to some extent with subject's usual function c) severe: AEs interferes significantly with subject's usual function.

End point type	Other pre-specified

End point timeframe:

Day 1 up to 7 days after last dose of study drug (up to 13 weeks)

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	97	94	
Units: events				
Mild	144	162	126	
Moderate	33	31	21	
Severe	7	3	5	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Child Behaviour Checklist (CBCL): Internalizing Subscale Score in Subjects Less Than 6 Years of Age

End point title	Child Behaviour Checklist (CBCL): Internalizing Subscale Score in Subjects Less Than 6 Years of Age

End point description:

CBCL assessed suicidal behavior in children below 6 years. It is 100-item questionnaire completed by parent/legal guardian, based on subject's behavior in past 2 months. All 100 items rated on 3-point scale: 0=not true for that child; 1=sometimes true; 2=very/often true. Total CBCL score ranges from 0 (not true) to 200 (very/often true). Higher scores=higher levels of problematic behaviors or dysfunction. Scores from all items were used to calculate 3 subscale scores: Withdrawn subscale scores, Internalizing problems subscale scores and total problem subscale scores. All subscale scores reported scaled to T Scores. In this study, a cut-off of >=68 on the T-scores was used for all 3 subscales. If a subject T Score was >=68 in any of the sub-scales, the subject was referred for Mental Health Risk Assessment that included assessment of subject continuation to the study. Safety population. N=subjects evaluable for endpoint, n=number of subjects evaluable for specific categories.

End point type	Other pre-specified

End point timeframe:

Week -8 (8 weeks prior to Day 1 of treatment), Week -4 (4 weeks prior to Day 1 of treatment), Day 1 (Week 0), Week 1, 2, 3, 6, 9, 12, end of study visit (Week 13)

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	14	14	
Units: T scores				
arithmetic mean (standard deviation)				
Week -8 (n= 12, 14, 14)	48.3 (± 12.12)	55.1 (± 9.37)	54.9 (± 11.15)	
Week -4 (n= 12, 14, 14)	48.1 (± 12.12)	50.9 (± 7.01)	52.6 (± 9.19)	
Week 0 (n= 12, 14, 14)	46.4 (± 14.14)	49.1 (± 7.08)	50.6 (± 9.61)	
Week 1 (n= 12, 13, 14)	46.3 (± 14.47)	48.7 (± 9.36)	50.7 (± 9.47)	
Week 2 (n= 11, 13, 13)	46.5 (± 14.45)	45.6 (± 8.21)	48.3 (± 10.93)	
Week 3 (n= 12, 14, 13)	45.6 (± 13.33)	44.2 (± 9.37)	49.6 (± 10.38)	
Week 6 (n= 11, 13, 11)	45.5 (± 16.73)	42.1 (± 9.65)	47.5 (± 15.19)	
Week 9 (n= 11, 13, 11)	46 (± 15.43)	40.6 (± 10.19)	51 (± 9.81)	
Week 12 (n= 11, 14, 13)	42.1 (± 11.99)	40.8 (± 8.95)	50.5 (± 8.91)	
Week 13 (n= 12, 14, 11)	44.3 (± 13.61)	39.9 (± 7.77)	50.8 (± 10.23)	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Child Behaviour Checklist (CBCL): Withdraw Subscale Score in Subjects Less Than 6 Years of Age

End point title	Child Behaviour Checklist (CBCL): Withdraw Subscale Score in Subjects Less Than 6 Years of Age

End point description:

CBCL assessed suicidal behavior in children below 6 years. It is 100-item questionnaire completed by parent/legal guardian, based on subject's behavior in past 2 months. All 100 items rated on 3-point scale: 0=not true for that child; 1=sometimes true; 2=very/often true. Total CBCL score ranges from 0 (not true) to 200 (very/often true). Higher scores=higher levels of problematic behaviors or dysfunction. Scores from all items were used to calculate 3 subscale scores: Withdrawn subscale scores, Internalizing problems subscale scores and total problem subscale scores. All subscale scores reported scaled to T Scores. In this study, a cut-off of >=68 on the T-scores was used for all 3 subscales. If a subject T Score was >=68 in any of the sub-scales, the subject was referred for Mental Health Risk Assessment that included assessment of subject continuation to the study Safety population. N= subjects evaluable for endpoint, n=number of subjects evaluable for specific categories.

End point type	Other pre-specified

End point timeframe:

Week -8 (8 weeks prior to Day 1 of treatment), Week -4 (4 weeks prior to Day 1 of treatment), Day 1 (Week 0), Week 1, 2, 3, 6, 9, 12, end of study visit (Week 13)

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	14	14	
Units: T scores				
arithmetic mean (standard deviation)				
Week -8 (n= 12, 14, 14)	56.4 (± 6.04)	64 (± 10.29)	63.1 (± 10.5)	
Week -4 (n= 12, 14, 14)	55.4 (± 5.43)	61.3 (± 8.99)	61.9 (± 10.48)	
Week 0 (n= 12, 14, 14)	56.6 (± 6.68)	60.6 (± 8.06)	60.9 (± 10.86)	
Week 1 (n= 12, 13, 14)	56.8 (± 7.12)	60.9 (± 10.01)	59.5 (± 10.09)	
Week 2 (n= 11, 13, 13)	56.3 (± 6.17)	60.2 (± 9.32)	59.2 (± 11.61)	
Week 3 (n= 12, 14, 13)	54.8 (± 6.8)	58.6 (± 8.53)	60.8 (± 11.02)	
Week 6 (n= 11, 13, 11)	55.5 (± 8.29)	56.6 (± 5.24)	54.5 (± 20.82)	
Week 9 (n= 11, 13, 11)	56.1 (± 6.99)	57.1 (± 7.3)	60 (± 10.64)	
Week 12 (n= 11, 14, 13)	54 (± 5.48)	57.3 (± 9.53)	59.6 (± 10.11)	
Week 13 (n= 12, 14, 11)	55.1 (± 6.43)	56.1 (± 7.21)	57.9 (± 10.58)	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Child Behaviour Checklist (CBCL): Total Problem Subscale Score in Subjects Less Than 6 Years of Age

End point title	Child Behaviour Checklist (CBCL): Total Problem Subscale Score in Subjects Less Than 6 Years of Age

End point description:

CBCL assessed suicidal behavior in children below 6 years. It is 100-item questionnaire completed by parent/legal guardian, based on subject's behavior in past 2 months. All 100 items rated on 3-point scale: 0=not true for that child; 1=sometimes true; 2=very/often true. Total CBCL score ranges from 0 (not true) to 200 (very/often true). Higher scores=higher levels of problematic behaviors or dysfunction. Scores from all items were used to calculate 3 subscale scores: Withdrawn subscale scores, Internalizing problems subscale scores and total problem subscale scores. All subscale scores reported scaled to T Scores. In this study, a cut-off of >=68 on the T-scores was used for all 3 subscales. If a subject T Score was >=68 in any of the sub-scales, the subject was referred for Mental Health Risk Assessment that included assessment of subject continuation to the study Safety population. N= subjects evaluable for endpoint, n=number of subjects evaluable for specific categories.

End point type	Other pre-specified

End point timeframe:

Week -8 (8 weeks prior to Day 1 of treatment), Week -4 (4 weeks prior to Day 1 of treatment), Day 1 (Week 0), Week 1, 2, 3, 6, 9, 12, end of study visit (Week 13)

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	14	14	
Units: T scores				
arithmetic mean (standard deviation)				
Week -8 (n= 12, 14, 14)	48 (± 10.84)	50.7 (± 11.48)	54.1 (± 10.94)	
Week -4 (n= 12, 14, 14)	47.8 (± 11.04)	47 (± 8.36)	52.5 (± 7.35)	

Week 0 (n= 12, 14, 14)	46.9 (± 11.75)	45.2 (± 7.79)	50.1 (± 8.81)	
Week 1 (n= 12, 13, 14)	46 (± 13.65)	43.8 (± 9.77)	50.1 (± 8.4)	
Week 2 (n= 11, 13, 13)	46.5 (± 13.17)	42.1 (± 7.77)	48.9 (± 8.95)	
Week 3 (n= 12, 14, 13)	46.4 (± 12.64)	42.4 (± 9.16)	49.5 (± 9.81)	
Week 6 (n= 11, 13, 11)	46.7 (± 15.25)	38.7 (± 5.95)	50.7 (± 8.86)	
Week 9 (n= 11, 13, 11)	47.6 (± 13.13)	38.4 (± 5.91)	51.2 (± 9.12)	
Week 12 (n= 11, 14, 13)	44.3 (± 11.78)	39 (± 8.94)	50.2 (± 9.28)	
Week 13 (n= 12, 14, 11)	45.5 (± 13.28)	37.9 (± 8.45)	51.6 (± 9.53)	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Week 12: Detection Task

End point title	Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Week 12: Detection Task

End point description:

CogState battery:computerized test battery assessing cognitive domains through cognition tasks. Test battery presented on computer with external response buttons.In the study,Cogstate battery:2 tasks to measure psychomotor function (detection task);attention (paediatric identification task).Detection task:measure of simple reaction time and provided a valid assessment of psychomotor function in subjects.In this task, a playing card turning face up was presented in the center of the computer screen.As soon this happened, the subject was to press the 'Yes' response key.There was no minimum or maximum scores as it was a time-based assessment.Software measured the speed of accurate responses to each event.In the endpoint,speed of performance of subjects(calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported.Lower scores=better performance.Safety population.N=subjects evaluable for endpoint,n=subjects evaluable for specific

End point type	Other pre-specified

End point timeframe:

Baseline (pre-dose at Day 1), Week 12

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	74	61	66	
Units: log10 milliseconds				
arithmetic mean (standard deviation)				
Baseline (n= 68, 56, 60)	2.71 (± 0.21)	2.72 (± 0.2)	2.7 (± 0.18)	
Change At Week 12 (n= 61, 45, 53)	0 (± 0.12)	-0.03 (± 0.12)	0.01 (± 0.09)	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Change From Baseline in Cognitive Test Battery (CogState

Battery) Score at Week 12: Paediatric Identification (Go-No Go: attention) Tasks

End point title	Change From Baseline in Cognitive Test Battery (CogState Battery) Score at Week 12: Paediatric Identification (Go-No Go: attention) Tasks

End point description:

CogState battery:computerized test battery assessing cognitive domains through cognition tasks.Test battery was presented on computer with external response buttons.Paediatric identification task:a measure of choice reaction time and valid assessment of visual attention.In this, a playing card turning face up was presented in center of the computer screen.As soon this happened, participant had to decide whether color of card was black or not.If color was black, subject was to press "Yes" response key, otherwise "no".No minimum/maximum scores as it was a time-based assessment.Software measured speed of accurate responses (correct identification of color) to each event. In this endpoint,speed of performance of subjects to correctly identify the color (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported.Lower scores=better performance.Safety population.N=subjects evaluable for endpoint,n=subjects evaluable for specific categories.

End point type	Other pre-specified

End point timeframe:

Baseline (pre-dose at Day 1), Week 12

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	74	61	66	
Units: log10 milliseconds				
arithmetic mean (standard deviation)				
Baseline (n= 67, 56, 59)	2.81 (± 0.15)	2.8 (± 0.15)	2.8 (± 0.14)	
Change At Week 12 (n= 60, 44, 51)	0 (± 0.11)	0 (± 0.12)	0 (± 0.1)	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Clinically Significant Laboratory Abnormalities

End point title	Number of Subjects With Clinically Significant Laboratory Abnormalities

End point description:

Criteria for abnormality:hematology (hemoglobin, hematocrit, red blood cells count:<0.8*lower limit of normal [LLN],platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN],leukocytes:<0.6*LLN or>1.5*ULN, lymphocytes, total neutrophils:<0.8*LLN or >1.2*ULN, basophils, eosinophil, monocytes:>1.2*ULN);Liver Function(aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase,Gamma glutamyl transferase:>0.3*ULN, total protein, albumin:<0.8*LLN or >1.2*ULN);bilirubin:>1.5*ULN;renal function(blood urea nitrogen, creatinine:>1.3*ULN);Electrolytes(sodium:<0.95*LLN or>1.05*ULN, potassium, chloride, calcium, bicarbonate:<0.9*LLN or >1.1*ULN);Lipids(cholesterol, triglycerides >1.3*ULN);creatine kinase:>2.0*ULN;glucose fasting:<0.6*LLN or >1.5*ULN,urine white blood corpuscles and RBC:>= 20/High Power Field [HPF];urine casts: >1/Low Power Field(LPF);urine bacteria:>20/HPF.Hormones (tetraiodothyronine and thyroid stimulating hormone:<0.8*LLN or >1.2*ULN).Safety population.

End point type	Other pre-specified

End point timeframe:

Baseline (from 8 weeks prior to Day 1 of treatment) up to Week 13

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	102	95	93	
Units: subjects	61	63	61	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Vital Signs Abnormalities

End point title	Number of Subjects With Vital Signs Abnormalities

End point description:

Criteria for abnormalities in vital signs included: sitting systolic blood pressure (SBP) values: maximum increase and decrease of >=30 millimeter of mercury (mmHg) from baseline; sitting diastolic blood pressure (DBP) value: maximum increase and decrease of >=20 mmHg from baseline. Safety population included all randomized subjects who took at least 1 dose of the study drug.Here,"N" signifies number of subjects who were evaluable for this endpoint.

End point type	Other pre-specified

End point timeframe:

Baseline (from 8 weeks prior to Day 1 of treatment) up to Week 13

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	98	93	92	
Units: subjects				
Maximum Increase from Baseline in Sitting SBP	2	1	1	
Maximum Increase from Baseline in Sitting DBP	6	8	11	
Maximum Decrease from Baseline in Sitting SBP	5	1	1	
Maximum Decrease from Baseline in Sitting DBP	15	6	10	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Clinically Significant Change From Baseline in Neurological Examinations at Week 13

End point title	Number of Subjects With Clinically Significant Change From Baseline in Neurological Examinations at Week 13

End point description:

Neurological examinations included: level of consciousness, mental status, cranial nerve assessment, muscle strength and tone, reflexes, pin prick and vibratory sensation (the latter using a 128-Hertz tuning fork), coordination and gait. Clinical significance was based on investigator's discretion.

End point type	Other pre-specified

End point timeframe:

Baseline (from 8 weeks prior to Day 1 of treatment) up to Week 13

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	97	94	
Units: subjects	0	1	0	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Electrocardiogram (ECG) Abnormalities

End point title	Number of Subjects With Electrocardiogram (ECG) Abnormalities

End point description:

Criteria for abnormalities in:1) Time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS complex):>=140 milliseconds (msec);2) The interval between the start of the P wave and the start of the QRS complex,corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval):>=200 msec;3)Time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia’s formula (QTCF interval):absolute value 450 to <480 msec, 480 to <500 msec, >=500 msec; 4) Maximum QT interval: >=500 msec;5) Maximum QTCB interval (Bazett’s correction):450 to< 480 msec,480 to <500 msec,>=500 msec.Only the categories of ECG abnormalities in which subjects were found abnormal, were reported in this endpoint.Safety population =all randomized subjects who took at least 1 dose of the study drug.Here,"N" signifies number of subjects who were evaluable for this endpoint.

End point type	Other pre-specified

End point timeframe:

Baseline (from 8 weeks prior to Day 1 of treatment) up to Week 13

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	102	97	94	
Units: subjects				
Maximum PR Interval	1	0	1	

Maximum QTCB Interval (Bazett's Correction)	2	0	2	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Clinically Significant Change From Baseline in Physical Examinations at Week 13

End point title	Number of Subjects With Clinically Significant Change From Baseline in Physical Examinations at Week 13

End point description:

Physical examinations evaluated the following body systems/organs: general appearance; dermatological; head and eyes; ears, nose, mouth, and throat; pulmonary; cardiovascular; abdominal; genitourinary (optional); lymphatic; musculoskeletal/extremities; and neurological. Clinical significance was determined by the investigator. Safety population included all randomized subjects who took at least 1 dose of the study drug.

End point type	Other pre-specified

End point timeframe:

Baseline (from 8 weeks prior to Day 1 of treatment) up to Week 13

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	97	94	
Units: subjects	5	5	2	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects (6-16 Years of Age) With Positive Response to Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories At Baseline

End point title	Number of Subjects (6-16 Years of Age) With Positive Response to Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories At Baseline

End point description:

C-SSRS (mapped to C-CASA):subject-rated questionnaire assessing suicidal ideation and suicidal behavior.For suicidal ideation and behaviour,data from C-SSRS was mapped to C-CASA codes 1, 2, 3, 4 and 7.C-SSRS assessed whether subject experienced following:completed suicide (C-CASA code 1);suicide attempt (response of "Yes" on "actual attempt")(C-CASA code 2);preparatory acts toward imminent suicidal behavior (ISB)("Yes" on "preparatory acts or behavior")(C-CASA code 3);suicidal ideation("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act,without specific plan or with specific plan and intent)

(C-CASA code 4);any self-injurious behavior with no suicidal intent (C-CASA code 7).In this endpoint, number of subjects with positive response (response of "yes") to C-SSRS (mapped to C-CASA categories 2, 3, 4 and 7) at baseline were reported.Safety population.N= subjects evaluable for endpoint.

End point type	Other pre-specified

End point timeframe:

Baseline (4 week prior to Day 1 of treatment)

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	92	81	80	
Units: subjects				
Suicide attempt (C-CASA code 2)	0	0	0	
Preparatory acts towards ISB (C-CASA code 3)	0	0	0	
Suicidal ideation (C-CASA code 4)	0	0	0	
Self injurious behavior (C-CASA code 7)	1	1	1	

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects (6-16 Years of Age) With Positive Response to Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories During Post Baseline Time Period

End point title	Number of Subjects (6-16 Years of Age) With Positive Response to Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories During Post Baseline Time Period

End point description:

C-SSRS (mapped to C-CASA):subject-rated questionnaire assessing suicidal ideation and suicidal behavior.For this,data from C-SSRS mapped to C-CASA codes 1, 2, 3, 4 and 7.C-SSRS assessed whether subject experienced following:completed suicide (C-CASA code 1); suicide attempt (response of "Yes" on "actual attempt") (C-CASA code 2);preparatory acts toward imminent suicidal behavior (ISB) ("Yes" on "preparatory acts or behavior")(C-CASA code 3);suicidal ideation("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent) (C-CASA code 4);any self-injurious behavior with no suicidal intent (C-CASA code 7). Number of subjects with positive response (response of "yes") to C-SSRS (mapped to C-CASA categories 1, 2, 3, 4 and 7) during post baseline time period (Day 1 up to Week 13) were reported. Safety population.N=subjects evaluable for endpoint.

End point type	Other pre-specified

End point timeframe:

Day 1 up to Week 13

End point values	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Pregabalin: 10 mg/kg/day or 14 mg/kg/day	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	91	83	80	
Units: subjects				
Completed suicide (C-CASA code 1)	0	0	0	
Suicide attempt (C-CASA code 2)	0	0	0	
Preparatory acts towards ISB (C-CASA code 3)	0	0	0	
Suicidal ideation (C-CASA code 4)	1	0	1	
Self injurious behavior (C-CASA code 7)	1	2	2	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 1 week after last dose of study drug (Week 13)

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.0

Reporting groups

Reporting group title	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day

Reporting group description:

Subjects aged 4 to 16 years and < 30 kg in weight, received pregabalin 3.5 mg/kg/day (up to a maximum of 150 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and >= 30 kg in weight, received pregabalin 2.5 mg/kg/day (up to a maximum of 150 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Reporting group title	Placebo

Reporting group description:

Subjects aged 4 to 16 years received placebo matched to pregabalin, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects <30 kg in weight received placebo in the form of oral solution while subjects >=30 kg in weight received placebo in the form of oral solution or capsule.

Reporting group title	Pregabalin: 10 mg/kg/day or 14 mg/kg/day

Reporting group description:

Subjects aged 4 to 16 years and < 30 kg in weight, received pregabalin 14 mg/kg/day (up to a maximum of 600 mg/day) oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months). Subjects aged 4 to 16 years and >= 30 kg in weight, received pregabalin 10 mg/kg/day (up to a maximum of 600 mg/day) capsule or oral solution, orally twice daily in equally divided doses, for the double-blind treatment phase of 12 weeks (3 months).

Serious adverse events	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Placebo	Pregabalin: 10 mg/kg/day or 14 mg/kg/day
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 104 (4.81%)	7 / 94 (7.45%)	10 / 97 (10.31%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Thermal burn			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Skin graft			

subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Drug withdrawal convulsions			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 104 (0.96%)	3 / 94 (3.19%)	3 / 97 (3.09%)
occurrences causally related to treatment / all	0 / 2	1 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Haematemesis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
Pneumonia aspiration			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Psychiatric disorders			
Hallucination			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			

subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Pregabalin: 2.5 mg/kg/day or 3.5 mg/kg/day	Placebo	Pregabalin: 10 mg/kg/day or 14 mg/kg/day
Total subjects affected by non-serious adverse events			
subjects affected / exposed	66 / 104 (63.46%)	55 / 94 (58.51%)	64 / 97 (65.98%)
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Hypotension			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 104 (0.96%)	2 / 94 (2.13%)	3 / 97 (3.09%)
occurrences (all)	2	2	4
Energy increased			

subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	6 / 104 (5.77%)	3 / 94 (3.19%)	4 / 97 (4.12%)
occurrences (all)	6	3	4
Feeling abnormal			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Feeling hot			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Gait disturbance			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	0	1	1
Pyrexia			
subjects affected / exposed	9 / 104 (8.65%)	7 / 94 (7.45%)	9 / 97 (9.28%)
occurrences (all)	10	8	10
Sluggishness			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	2 / 97 (2.06%)
occurrences (all)	0	0	9
Reproductive system and breast disorders			
Breast swelling			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Pruritus genital			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Bronchial obstruction			

subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	0 / 104 (0.00%)	2 / 94 (2.13%)	2 / 97 (2.06%)
occurrences (all)	0	3	2
Cough			
subjects affected / exposed	9 / 104 (8.65%)	3 / 94 (3.19%)	2 / 97 (2.06%)
occurrences (all)	9	3	2
Hypopnoea			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Interstitial lung disease			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Nasal congestion			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	2
Oropharyngeal pain			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	2
Rhinitis allergic			
subjects affected / exposed	2 / 104 (1.92%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	2	1	0
Rhinorrhoea			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	2 / 97 (2.06%)
occurrences (all)	1	0	3
Wheezing			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Aggression			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0

Agitation			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	1	0	1
Disinhibition			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Initial insomnia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	0	1	1
Insomnia			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	1	0	1
Irritability			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	3 / 97 (3.09%)
occurrences (all)	1	1	3
Middle insomnia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Mood altered			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Mutism			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Mood swings			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Sleep disorder			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Nervousness			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Tic			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1

Investigations			
Body temperature increased			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyl transferase increased			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Heart rate decreased			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	2	0	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Weight increased			
subjects affected / exposed	4 / 104 (3.85%)	4 / 94 (4.26%)	13 / 97 (13.40%)
occurrences (all)	4	4	13
White blood cell count increased			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Animal bite			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	1	0	1
Contusion			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	2 / 97 (2.06%)
occurrences (all)	1	1	4
Ear abrasion			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Eye contusion			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	2 / 97 (2.06%)
occurrences (all)	0	0	2
Fall			

subjects affected / exposed	1 / 104 (0.96%)	2 / 94 (2.13%)	2 / 97 (2.06%)
occurrences (all)	1	2	5
Head injury			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Laceration			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Ligament sprain			
subjects affected / exposed	2 / 104 (1.92%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	2	0	0
Limb injury			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Lip injury			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Periorbital haematoma			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	0	1	1
Scar			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Scratch			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Skin abrasion			
subjects affected / exposed	1 / 104 (0.96%)	3 / 94 (3.19%)	2 / 97 (2.06%)
occurrences (all)	2	3	2
Soft tissue injury			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Thermal burn			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Wound			

subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	1	0	1
Cardiac disorders			
Atrioventricular block first degree			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Aphasia			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Balance disorder			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Clonus			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Disturbance in attention			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	1	0	1
Dizziness			
subjects affected / exposed	4 / 104 (3.85%)	1 / 94 (1.06%)	3 / 97 (3.09%)
occurrences (all)	5	1	3
Headache			
subjects affected / exposed	4 / 104 (3.85%)	6 / 94 (6.38%)	7 / 97 (7.22%)
occurrences (all)	4	17	12
Hypersomnia			
subjects affected / exposed	2 / 104 (1.92%)	2 / 94 (2.13%)	1 / 97 (1.03%)
occurrences (all)	2	2	1
Lethargy			
subjects affected / exposed	2 / 104 (1.92%)	0 / 94 (0.00%)	2 / 97 (2.06%)
occurrences (all)	2	0	2
Migraine			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Nystagmus			

subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Partial seizures with secondary generalisation			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	2	1	1
Poor quality sleep			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Psychomotor hyperactivity			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Seizure			
subjects affected / exposed	6 / 104 (5.77%)	4 / 94 (4.26%)	1 / 97 (1.03%)
occurrences (all)	11	5	1
Somnolence			
subjects affected / exposed	18 / 104 (17.31%)	13 / 94 (13.83%)	25 / 97 (25.77%)
occurrences (all)	23	16	50
Tunnel vision			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Lymphadenitis			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	2 / 104 (1.92%)	0 / 94 (0.00%)	3 / 97 (3.09%)
occurrences (all)	2	0	5
Eye disorders			
Asthenopia			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Blepharospasm			

subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Diplopia			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	10
Eye swelling			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Hypermetropia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Myopia			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Vision blurred			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Visual brightness			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Visual impairment			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	3 / 104 (2.88%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	4	1	0
Abdominal pain upper			
subjects affected / exposed	0 / 104 (0.00%)	3 / 94 (3.19%)	0 / 97 (0.00%)
occurrences (all)	0	3	0
Constipation			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	3 / 97 (3.09%)
occurrences (all)	1	1	3
Dental caries			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0

Diarrhoea			
subjects affected / exposed	0 / 104 (0.00%)	4 / 94 (4.26%)	5 / 97 (5.15%)
occurrences (all)	0	4	6
Enterocolitis			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Lip dry			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	3 / 104 (2.88%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	4	2	0
Oral pain			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Retching			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Salivary hypersecretion			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	4 / 97 (4.12%)
occurrences (all)	1	0	19
Tongue disorder			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Tooth disorder			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Tooth erosion			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1

Toothache			
subjects affected / exposed	1 / 104 (0.96%)	2 / 94 (2.13%)	0 / 97 (0.00%)
occurrences (all)	1	2	0
Vomiting			
subjects affected / exposed	5 / 104 (4.81%)	4 / 94 (4.26%)	4 / 97 (4.12%)
occurrences (all)	6	4	5
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	2 / 97 (2.06%)
occurrences (all)	0	0	3
Erythema			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Rash erythematous			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Rash maculo-papular			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	2	0
Skin erosion			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Myalgia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0

Infections and infestations			
Ascariasis			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Bronchitis			
subjects affected / exposed	1 / 104 (0.96%)	3 / 94 (3.19%)	2 / 97 (2.06%)
occurrences (all)	1	3	2
Conjunctivitis			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	1	0	1
Conjunctivitis viral			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Cystitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Dermatitis infected			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Ear infection			
subjects affected / exposed	0 / 104 (0.00%)	2 / 94 (2.13%)	0 / 97 (0.00%)
occurrences (all)	0	2	0
Gastroenteritis			
subjects affected / exposed	1 / 104 (0.96%)	3 / 94 (3.19%)	0 / 97 (0.00%)
occurrences (all)	1	3	0
Gastroenteritis viral			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Gastrointestinal candidiasis			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal viral infection			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	1	1	0
Nasopharyngitis			

subjects affected / exposed	9 / 104 (8.65%)	6 / 94 (6.38%)	7 / 97 (7.22%)
occurrences (all)	9	8	8
Otitis media			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Parasitic gastroenteritis			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	2 / 104 (1.92%)	2 / 94 (2.13%)	3 / 97 (3.09%)
occurrences (all)	2	3	3
Pharyngotonsillitis			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	1	0	1
Pneumonia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Rash pustular			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	0 / 104 (0.00%)	2 / 94 (2.13%)	0 / 97 (0.00%)
occurrences (all)	0	3	0
Respiratory tract infection viral			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Rhinitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	0	1	1
Skin infection			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Tonsillitis			

subjects affected / exposed	1 / 104 (0.96%)	2 / 94 (2.13%)	1 / 97 (1.03%)
occurrences (all)	1	2	1
Upper respiratory tract infection			
subjects affected / exposed	10 / 104 (9.62%)	9 / 94 (9.57%)	8 / 97 (8.25%)
occurrences (all)	11	12	10
Varicella			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	1 / 104 (0.96%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	1	1	1
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	0	1	1
Viral infection			
subjects affected / exposed	2 / 104 (1.92%)	0 / 94 (0.00%)	3 / 97 (3.09%)
occurrences (all)	2	0	3
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	1 / 97 (1.03%)
occurrences (all)	0	1	1
Dehydration			
subjects affected / exposed	0 / 104 (0.00%)	0 / 94 (0.00%)	1 / 97 (1.03%)
occurrences (all)	0	0	1
Hyperphagia			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0
Hyponatraemia			
subjects affected / exposed	0 / 104 (0.00%)	1 / 94 (1.06%)	0 / 97 (0.00%)
occurrences (all)	0	1	0
Increased appetite			
subjects affected / exposed	7 / 104 (6.73%)	4 / 94 (4.26%)	10 / 97 (10.31%)
occurrences (all)	7	4	10
Overweight			
subjects affected / exposed	1 / 104 (0.96%)	0 / 94 (0.00%)	0 / 97 (0.00%)
occurrences (all)	1	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 November 2011	1- Clarified that mentally or physically handicapped subjects do not have to complete CogState if they are unable.2- Clarified procedure if dose escalation phase not tolerated.3- Clarified that Greek and Cebuano speaking subjects/parents will be excluded. Greek and Cebuano subjects age 6 years and older can be included.4- Added "allergy to pregabalin or excipients…" in exclusion criteria 18.5- On SOA, footnote "d", added information on need for additional pregnancy tests based upon local regulations.
16 March 2015	1-Section 3.1 Screening and Baseline: AED changed to anti-epileptic treatments which include VNS; further detail added to diagnostic and risk assessment procedures.2- Section 4.3.1 Contraceptive Guidelines: updated with current standard wording.3- Section 7.2.1 Assessment of Suicidal Ideation: clarifications added.4- Section 9.4 Interim Safety Analysis: added clarifying text regarding E-DMC.5- Protocol Summary: updated, Lyrica approved in 130 countries, considered a PASS study, external DMC added.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported